drugset / Trial / NCT00479128
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or other solid tumors.
Timeline
- Start
- 2006-09-28
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.8 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 12.5 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 225 mg/m2 | Intravenous |